Goldman Sachs’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Goldman Sachs’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-30,000	Closed	-$515K	–	6157
2018 Q1	$515K	Hold	30,000	–	–	﹤0.01%	4475
2017 Q4	$658K	Buy	+30,000	New	+$965K	﹤0.01%	4612
2016 Q3	–	Sell	-29,300	Closed	-$1.21M	–	7261
2016 Q2	$1.21M	Sell	29,300 -50,000	-63%	-$2.17M	﹤0.01%	4035
2016 Q1	$3.22M	Buy	+79,300	New	+$2.73M	﹤0.01%	3075

Goldman Sachs's FPRX Position: Q2 2021 in Review

Goldman Sachs sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 1,397,403 shares — an estimated $52.6M sold.

Goldman Sachs first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $52.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Goldman Sachs reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Goldman Sachs sold 1,397,403 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $52.6M.
Goldman Sachs first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
Goldman Sachs's Five Prime Therapeutics, Inc. position peaked at $52.6M in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.